Glycan biomarkers of autoimmunity and bile acid-associated alterations of the human glycome Primary biliary cirrhosis and primary sclerosing cholangitis-specific glycans

Glycan biomarkers of autoimmunity and bile acid-associated alterations of the human glycome : Primary biliary cirrhosis and primary sclerosing cholangitis-specific glycans

Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 230(2021) vom: 08. Sept., Seite 108825
1. Verfasser: Maverakis, Emanual (VerfasserIn)
Weitere Verfasser: Merleev, Alexander A, Park, Dayoung, Kailemia, Muchena J, Xu, Gege, Ruhaak, L Renee, Kim, Kyoungmi, Hong, Qiuting, Li, Qiongyu, Leung, Patrick, Liakos, William, Wan, Yu-Jui Yvonne, Bowlus, Christopher L, Marusina, Alina I, Lal, Nelvish N, Xie, Yixuan, Luxardi, Guillaume, Lebrilla, Carlito B
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2021
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Multiple Reaction Monitoring N-glycopeptides Primary Biliary Cirrhosis (PBC) Primary Sclerosing Cholangitis (PSC) biomarker testing plasma Bile Acids and Salts mehr... Biomarkers Glycopeptides Polysaccharides
LEADER 01000caa a22002652c 4500
001 NLM329474006
003 DE-627
005 20250302091310.0
007 cr uuu---uuuuu
008 231225s2021 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2021.108825  |2 doi 
028 5 2 |a pubmed25n1098.xml 
035 |a (DE-627)NLM329474006 
035 |a (NLM)34403816 
035 |a (PII)S1521-6616(21)00162-5 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Maverakis, Emanual  |e verfasserin  |4 aut 
245 1 0 |a Glycan biomarkers of autoimmunity and bile acid-associated alterations of the human glycome  |b Primary biliary cirrhosis and primary sclerosing cholangitis-specific glycans 
264 1 |c 2021 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 13.09.2021 
500 |a Date Revised 05.11.2021 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved. 
520 |a We have recently introduced multiple reaction monitoring (MRM) mass spectrometry as a novel tool for glycan biomarker research and discovery. Herein, we employ this technique to characterize the site-specific glycan alterations associated with primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). Glycopeptides associated with disease severity were also identified. Multinomial regression modelling was employed to construct and validate multi-analyte diagnostic models capable of accurately distinguishing PBC, PSC, and healthy controls from one another (AUC = 0.93 ± 0.03). Finally, to investigate how disease-relevant environmental factors can influence glycosylation, we characterized the ability of bile acids known to be differentially expressed in PBC to alter glycosylation. We hypothesize that this could be a mechanism by which altered self-antigens are generated and become targets for immune attack. This work demonstrates the utility of the MRM method to identify diagnostic site-specific glycan classifiers capable of distinguishing even related autoimmune diseases from one another 
650 4 |a Journal Article 
650 4 |a Research Support, N.I.H., Extramural 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Multiple Reaction Monitoring 
650 4 |a N-glycopeptides 
650 4 |a Primary Biliary Cirrhosis (PBC) 
650 4 |a Primary Sclerosing Cholangitis (PSC) 
650 4 |a biomarker testing 
650 4 |a plasma 
650 7 |a Bile Acids and Salts  |2 NLM 
650 7 |a Biomarkers  |2 NLM 
650 7 |a Glycopeptides  |2 NLM 
650 7 |a Polysaccharides  |2 NLM 
700 1 |a Merleev, Alexander A  |e verfasserin  |4 aut 
700 1 |a Park, Dayoung  |e verfasserin  |4 aut 
700 1 |a Kailemia, Muchena J  |e verfasserin  |4 aut 
700 1 |a Xu, Gege  |e verfasserin  |4 aut 
700 1 |a Ruhaak, L Renee  |e verfasserin  |4 aut 
700 1 |a Kim, Kyoungmi  |e verfasserin  |4 aut 
700 1 |a Hong, Qiuting  |e verfasserin  |4 aut 
700 1 |a Li, Qiongyu  |e verfasserin  |4 aut 
700 1 |a Leung, Patrick  |e verfasserin  |4 aut 
700 1 |a Liakos, William  |e verfasserin  |4 aut 
700 1 |a Wan, Yu-Jui Yvonne  |e verfasserin  |4 aut 
700 1 |a Bowlus, Christopher L  |e verfasserin  |4 aut 
700 1 |a Marusina, Alina I  |e verfasserin  |4 aut 
700 1 |a Lal, Nelvish N  |e verfasserin  |4 aut 
700 1 |a Xie, Yixuan  |e verfasserin  |4 aut 
700 1 |a Luxardi, Guillaume  |e verfasserin  |4 aut 
700 1 |a Lebrilla, Carlito B  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 230(2021) vom: 08. Sept., Seite 108825  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnas 
773 1 8 |g volume:230  |g year:2021  |g day:08  |g month:09  |g pages:108825 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2021.108825  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 230  |j 2021  |b 08  |c 09  |h 108825